Haste makes waste : should current guideline recommendations for initiation of renal replacement therapy for acute kidney injury be changed? by Vanmassenhove, Jill et al.
E D I T O R I A L
Haste makes waste—Should current guideline
recommendations for initiation of renal replacement therapy
for acute kidney injury be changed?
Abstract
There is broad consensus among guideline organizations that renal
replacement therapy (RRT) should not be delayed in case of life-
threatening conditions. However, in case of severe acute kidney
injury (AKI) without these conditions, it is unclear whether imme-
diate RRT has an advantage over delayed RRT. Two recently pub-
lished randomized controlled trials (AKIKI and ELAIN) with
seemingly opposite results have reignited the discussion whether
guideline recommendations on initiation strategies in severe AKI
should be adapted. This editorial discusses RRT initiation strategies
in severe AKI, based on recent literature and highlights the poten-
tial advantages and disadvantages of immediate vs delayed start.
Overall, evidence in favor of immediate compared to delayed
strategies is sparse and there is wide heterogeneity across studies
making it difficult to draw firm conclusions. RRT should not be
delayed in case of refractory hyperkalemia, severe metabolic aci-
dosis or pulmonary edema resistant to diuretics. In all other cases,
a delayed strategy seems justified and might enhance renal recov-
ery. RRT is not a “it doesn’t hurt to try” technique and can
expose the patient to a higher risk of bleeding, hemodynamic
problems, under-dosing of antibiotics, loss of nutrients, catheter-
related complications and the uncertain effects of blood-membrane
interactions. There is no compelling reason to change current
guideline recommendations and research focus should shift toward
the development of algorithms as a decision aid tool for RRT initi-
ation in severe AKI.
1 | INTRODUCTION
The annual incidence of acute kidney injury (AKI) managed with
renal replacement therapy (RRT) has increased over time,1 and cur-
rently about 8%-12% of ICU patients receive RRT.2 This increase
may reflect changes in either the occurrence of severe AKI or prac-
tice shifts in the thresholds for initiating RRT. The decision to start
RRT is unequivocal in the presence of life-threatening AKI complica-
tions, but in their absence the optimal timing of RRT initiation for
AKI remains uncertain, in particular since 2 recently published ran-
domized trials showed seemingly opposite results.3,4 This has reig-
nited the discussion whether or not early start has a benefit over
late start of RRT in AKI.
The decision to start RRT can, in these circumstances, be dri-
ven by a number of factors such as clinical symptoms, serum
solute levels, severity of AKI, prognostic scores, number of failed
organs, and even availability of equipment and personnel.5 This
results in a wide variety of indications for and differences in
prevalence of AKI requiring RRT. This discrepancy in indications
also blurs interpretation of differences in outcome between studies
and institutions.
This editorial discusses recent trials comparing early/immediate
vs late/delayed RRT and provides a background summary for clini-
cians involved in making decisions on RRT initiation, irrespective of
the modality offered (intermittent hemodialysis, peritoneal dialysis,
continuous RRT, or slow extended hemodialysis). Specific conditions
where hard indications for RRT other than just AKI can be consid-
ered, such as acute tumor lysis syndrome, severe rhabdomyolysis, or
intoxications with toxic alcohols, lithium, salicylate, theophylline or
valproate, will not be covered.
2 | WHAT DO THE GUIDELINES SAY?
There is broad consensus among guidance bodies that RRT
should not be deferred in what are called “life-threatening con-
ditions”.6-10 Most guidelines explicitly state that clinicians should
consider the broader clinical context, the presence of conditions
that can be modified by RRT, and trends of laboratory tests
rather than single thresholds when making the decision to
start.11 However, there seems to be no consensus on what
exactly is meant by “life-threatening conditions,” and what the
thresholds of laboratory parameters should be. Table 1 lists
some of these parameters and their suggested thresholds.12,13 It
is clear that for most of these criteria, hard evidence to support
their validity is lacking, since they are based on incorrect extrap-
olations from observational studies, thus mixing cause and con-
sequence.
For example, data demonstrating an association between dismal
outcome and hyperkalemia are largely retrospective.14 In a study by
McMahon et al,15 potassium concentrations at ICU admission and
duration of hyperkalemia are strong predictors of all-cause mortality
with a significant risk gradient across serum potassium strata, but
this is probably explained by the association of hyperkalemia itself
with worse disease conditions. The use of RRT for management of
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hyperkalemia has not been associated with improved survival,
whereas more conservative treatments such as IV calcium or insulin/
dextrose are.14,16 The underlying explanations are complex ranging
from the fact that RRT is indeed inferior, from higher complication
rates for RRT wiping out potential benefits, from the perils of a too
rapid correction of potassium, from more sick patients receiving RRT
(selection bias) or from RRT being the last resort (indication bias).
Further studies should explore the mechanisms underlying these
observations.
Similarly, no studies exist delineating a clearly defined threshold
for initiation of RRT in AKI patients with metabolic acidosis; studies
are needed which examine improvement of clinically relevant, rather
than surrogate, outcomes. However, in the absence of severe respi-
ratory acidosis, a pH below 7.15 with an intractable metabolic acido-
sis is a generally accepted indication for RRT.
Uremia, often assessed by measurement of serum urea, is
itself commonly used as an indication to start RRT. However, urea
is not an ideal marker, as its generation and volume of distribu-
tion are highly variable in critically ill patients. At present, no gen-
erally accepted threshold based on a definitive urea concentration
exists. Substantial azotemia [suggested by urea concentrations
>30 mmol/L (BUN 84 mg/dL) or creatinine concentrations
>300 lmol/L (3.4 mg/dL)] is judged a marker of an undesirable
toxic state. However, no recommendations indicate what severity
of acute azotemia can be tolerated. We agree with Bellomo
et al17 that this degree of azotemia should probably be treated
with RRT unless recovery is imminent or already under way, or a
return toward normal urea and creatinine concentrations is
expected within 24-48 hours (eg, in transient AKI) such as is seen
with severe volume depletion.
In case of metabolic derangements, it is also important to con-
sider that some patients are more vulnerable than others due to the
presence of certain comorbidities. Such derangements should be
considered in the decision to initiate dialysis.
Multiple studies have demonstrated that the severity of volume
overload at initiation of RRT is a strong predictor of mortality.18,19
There is general agreement that in AKI patients volume overload
with pulmonary edema resistant to diuretics is a formal indication
for initiation of RRT and ultrafiltration.17
3 | WHAT ARE THE POTENTIAL
ADVANTAGES AND DISADVANTAGES OF
STARTING RRT EARLY VS LATE?
Early/immediate initiation strategies could theoretically be advanta-
geous because of more rapid equilibration of acid-base status, avoid-
ance of cardiac arrhythmias, and easier control of fluid balance. So
far, however, no study has evaluated the attributable mortality of
RRT requiring AKI. This attributable mortality is the number of
deaths due to the presence of AKI itself rather than any associated
or underlying comorbidities. This is of importance in the discussion
on timing of start of RRT, as the attributable mortality is the maxi-
mum to be gained with the treatment being 100% effective and hav-
ing no side effects. Outside of the conditions associated with “hard”
indications to start RRT, the causal impact of AKI on mortality is pre-
sumably low. Studies indicate that only patients with AKI complica-
tions have a better survival when RRT was initiated.20
Therefore, it seems unlikely that a broader application of RRT
would have any significant impact on mortality.21 In addition, dialysis
is not a “it doesn’t hurt to try” technique and can expose the patient
to a higher risk of bleeding, under-dosing of antibiotics, loss of nutri-
ents and catheter-related infectious and noninfectious complications.
Recovery of renal function can be jeopardized, partly due to higher
risk of hemodynamic instability during RRT. Such instability may also
have cardiac and neurologic complications. Rapid correction of acido-
sis can enhance a further decrease in calcium levels causing arrhyth-
mia. The consequences of blood-membrane interactions are uncertain
but may well be harmful. Especially in CRRT, there is a risk for devel-
opment of hypophosphatemia which can lead to muscle weakness and
prolonged respiratory failure which is associated with higher mortal-
ity.22-24 In observational trials, use of RRT is independently associated
with mortality.20,21,25-28 A too early start can thus be harmful.29
4 | TRIALS ON EARLY VS LATE START OF
RRT
Until recently, we mainly had to rely on data from retrospective
studies30-33 comparing early vs late RRT. Although these studies
TABLE 1 Currently accepted “conventional” or “absolute” indications for initiation of renal replacement therapy
Parameter Definition
Hyperkalemia Serum potassium ≥6.5 mmol/L, or rapidly rising potassium, or refractory to standard supportive medical management
Metabolic acidosis pH ≤7.15
Uremia Urea >36 mmol/L (BUN = 101 mg/dL, blood urea = 216 mg/dL)
Oliguria or anuria Urine output <0.3 mL kg1 h1 for ≥24 h or anuria for ≥12 h
Fluid overload Pulmonary edema not responding to diuretics and defined by the presence of all of the following factors:
1. >10% fluid accumulation (cumulative fluid balance/baseline weight >10%)
2. oliguria (urine output <0.5 mL kg1 h1 for ≥12 h) and
3. Severely impaired oxygenation (PaO2/FiO2 < 200 indicated by respiratory Sequential Organ Failure Assessment
(SOFA) score ≥3)
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generally favored an early start, the paucity of RCT’s34-37 and the
heterogeneity across studies made it difficult to draw firm conclu-
sions. Several meta-analyses,38,39 mainly of retrospective studies,
concluded that there was a potential benefit for early start of RRT.
However, these meta-analyses were biased by mixing up observa-
tional and randomized studies with great heterogeneity across stud-
ies. One of the major contributors to the heterogeneity was the
varying definition of “early” vs “late” with time factors, clinical fac-
tors or biochemical factors all being used. Another problem in obser-
vational studies is the immortal time bias induced by excluding
patients who recover renal function before RRT is needed, rather
than considering them as “late starters”. In excluding these patients
with an excellent prognosis from the analysis, the outcome of the
delayed RRT group is penalized.
Since the publication of these meta-analyses, several randomized
controlled studies have appeared that do not support the concept
that early RRT is beneficial40-44 and a more recent meta-analysis45
including these studies, does not support the conclusion of the pre-
vious meta-analyses.
In 2016, 2 RCT’s (the ELAIN and AKIKI trial)3,4 on immediate vs
delayed RRT were published, with seemingly opposite results. Both
studies were intention-to-treat and thus also included in the analysis
patients who were randomized but had no need to be started on
RRT. However, these studies were very different in their
approach.46,47 The ELAIN study included patients with predomi-
nantly postsurgical KDIGO stage 2 AKI and either septic shock or
refractory fluid overload. RRT modality and dose were defined as
continuous veno-venous hemodiafiltration (CVVHDF) at
30 mL kg1 h1 with 100% predilution and 1:1 ratio of dialysate to
replacement fluid. Patients randomized to the early start group were
started on dialysis within 8 hours after inclusion. Patients random-
ized to the delayed start group were only started on RRT within
12 hours of reaching KDIGO stage 3. In the latter group, over 90%
of patients with stage 3 KDIGO AKI were eventually treated with
RRT. This is no surprise, as almost 75% of patients were diagnosed
with fluid overload or worsening pulmonary edema and had thus in
fact a “hard” indication to start RRT already before randomization.
One could thus summarize that ELAIN investigated the effect of
delaying dialysis in those who really needed it. It is thus not surpris-
ing that the conclusion of the ELAIN study was that an early vs
delayed start improved patient outcome.
In contrast, the AKIKI trial excluded patients with established
criteria to start dialysis, such as severe hyperkalemia or pulmonary
edema. Patients not meeting exclusion criteria were included from
the moment they reached KDIGO stage 3. Dialysis modality was
mixed intermittent and/or continuous RRT and the dialysis dose
was at the discretion of the treating physician. Patients random-
ized to the early group in the AKIKI trial were started on RRT
within 6 hours of randomization whereas those randomized to the
delayed start group were only to be started on RRT whenever
they met one of the predefined “absolute” criteria. AKIKI showed
no superiority for early initiation of RRT. In the delayed start
group, RRT was avoided in around 50% of patients (vs only in 9%
in the ELAIN trial). In a recent post hoc analysis of this trial,48
subgroups of patients with sepsis, ARDS and tertiles of baseline
illness severity score were investigated. Results confirmed that
there was no advantage for an early dialysis initiation strategy in
these subgroups.
What do these studies teach us? Most important, the terms
“early” vs “late” should better be replaced by “immediate” and “de-
layed” RRT, and should be based on well-established criteria rather
than classification criteria or biomarkers. Next, RRT should not be
deferred in those who really need it. As described above, the only
absolute indications for dialysis therapy in severe AKI are significant
volume overload refractory to diuretics, refractory hyperkalemia and
refractory metabolic acidosis.49 In the absence of these criteria, a
“wait and see” approach is justified. When making a decision, one
should not focus on specific thresholds but take a holistic view on
the patient’s clinical condition. Instead of eagerly awaiting the results
of further trials comparing early vs late (eg, IDEAL-ICU50 and
STARRT-AKI51), the research community should focus on developing
algorithms to help clinicians in their decision making and elucidate
the underlying behavior/attitudes that drive decision making to start
dialysis.52
5 | CONCLUSION
When life-threatening conditions are present, RRT should not be
delayed. In all other cases, an “expectatio armata” approach seems
justified. There is no hard evidence that, in the absence of estab-
lished criteria, early start of RRT improves outcome. RRT is not a
harmless intervention and starting too early imposes unnecessary
risks to the patient and might jeopardize renal recovery. The focus
of research should shift to developing algorithms helping clinicians in
their decision-making process.
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